Population attributable fraction of infection-related cancers in Korea

A number of infectious agents have been classified as human carcinogens. The purpose of the current study was to provide an evidence-based assessment of the burden of infection-related cancers in the Korean population. The population attributable fraction was calculated using infection prevalence da...

Full description

Saved in:
Bibliographic Details
Published in:Annals of oncology Vol. 22; no. 6; pp. 1435 - 1442
Main Authors: Shin, A., Park, S., Shin, H.R., Park, E.-H., Park, S.K., Oh, J.-K., Lim, M.-K., Choi, B.Y., Boniol, M., Boffetta, P.
Format: Journal Article
Language:English
Published: Oxford Elsevier Ltd 01-06-2011
Oxford University Press
Subjects:
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:A number of infectious agents have been classified as human carcinogens. The purpose of the current study was to provide an evidence-based assessment of the burden of infection-related cancers in the Korean population. The population attributable fraction was calculated using infection prevalence data from 1990 or earlier, relative risk estimates from meta-analyses using mainly Korean studies and national data on cancer incidence and mortality for the year 2007. The fractions of all cancers attributable to infection were 25.1% and 16.8% for cancer incidence in men and women, and 25.8% and 22.7% of cancer mortality in men and women, respectively. Among infection-related cancers, Helicobacter pylori was responsible for 56.5% of cases and 45.1% of deaths, followed by hepatitis B virus (HBV) (23.9% of cases and 37.5% of deaths) and human papillomavirus (HPV) (11.3% of cases and 6% of deaths) and then by hepatitis C virus (HCV) (6% of cases and 9% of deaths). Over 97% of infection-related cancers were attributable to infection with H. pylori, HBV, HCV and HPV. Up to one-quarter of cancer cases and deaths would be preventable through appropriate control of infectious agents in Korea.
ISSN:0923-7534
1569-8041
DOI:10.1093/annonc/mdq592